文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

低级别动静脉畸形的治疗。

Curative treatment for low-grade arteriovenous malformations.

机构信息

Neurosurgery and Radiology, Columbia University Medical Center, New York City, New York, USA.

Neurosurgery, Columbia University Medical Center, New York City, New York, USA.

出版信息

J Neurointerv Surg. 2020 Jan;12(1):48-54. doi: 10.1136/neurintsurg-2019-015115. Epub 2019 Jul 12.


DOI:10.1136/neurintsurg-2019-015115
PMID:31300533
Abstract

BACKGROUND: Spetzler-Martin (SM) grade I-II (low-grade) arteriovenous malformations (AVMs) are often considered safe for microsurgery or radiosurgery. The adjunctive use of preoperative embolization to reduce surgical risk in these AVMs remains controversial. OBJECTIVE: To assess the safety of combined treatment of grade I-II AVMs with preoperative embolization followed by surgical resection or radiosurgery, and determine the long-term functional outcomes. METHODS: With institutional review board approval, a retrospective analysis was carried out on patients with ruptured and unruptured SM I-II AVMs between 2002 and 2017. Details of the endovascular procedures, including number of arteries supplying the AVM, number of branches embolized, embolic agent(s) used, and complications were studied. Baseline clinical and imaging characteristics were compared. Functional status using the modified Rankin Scale (mRS) before and after endovascular and microsurgical treatments was compared. RESULTS: 258 SM I-II AVMs (36% SM I, 64% SM II) were identified in patients with a mean age of 38 ± 17 years. 48% presented with hemorrhage, 21% with seizure, 16% with headache, 10% with no symptoms, and 5% with clinical deficits. 90 patients (68%) in the unruptured group and 74 patients (59%) in the ruptured group underwent presurgical embolization (p = 0.0013). The mean number of arteries supplying the AVM was 1.44 and 1.41 in the unruptured and ruptured groups, respectively (p = 0.75). The mean number of arteries embolized was 2.51 in the unruptured group and 1.82 in the ruptured group (p = 0.003). n-Butyl cyanoacrylate and Onyx were the two most commonly used embolic agents. Four complications were seen in four patients (4/164 patients embolized): two peri-/postprocedural hemorrhage, one dissection, and one infarct. All patients undergoing surgery had a complete cure on postoperative angiography. Patients were followed up for a mean of 55 months. Good long-term outcomes (mRS score ≤ 2) were seen in 92.5% of patients with unruptured AVMs and 88.0% of those with ruptured AVMs. Permanent neurological morbidity occurred in 1.2%. CONCLUSIONS: Curative treatment of SM I-II AVMs can be performed using endovascular embolization with microsurgical resection or radiosurgery in selected cases, with very low morbidity and high cure rates. Compared with other published series, these outcomes suggest that preoperative embolization is a safe and effective adjunct to definitive surgical treatment. Long-term follow-up showed that patients with low-grade AVMs undergoing surgical resection or radiosurgery have good functional outcomes.

摘要

背景:斯佩茨勒-马丁(Spetzler-Martin,SM)分级 I-II(低级别)动静脉畸形(AVM)通常被认为可以安全地进行显微手术或放射外科手术治疗。在这些 AVM 中,术前栓塞术辅助降低手术风险的效果仍存在争议。 目的:评估术前栓塞联合显微切除术或放射外科手术治疗 SM I-II 级 AVM 的安全性,并确定其长期功能结果。 方法:经机构审查委员会批准,回顾性分析了 2002 年至 2017 年间患有破裂和未破裂 SM I-II AVM 的患者。研究了血管内治疗的详细信息,包括供应 AVM 的动脉数量、栓塞分支数量、使用的栓塞剂以及并发症等。比较了基线临床和影像学特征。比较了血管内和显微外科治疗前后改良 Rankin 量表(mRS)的功能状态。 结果:在患者中发现了 258 例 SM I-II AVM(36%为 SM I 级,64%为 SM II 级),平均年龄为 38±17 岁。48%的患者表现为出血,21%的患者表现为癫痫发作,16%的患者表现为头痛,10%的患者无症状,5%的患者有临床缺损。未破裂组中有 90 例(68%)和破裂组中有 74 例(59%)患者接受了术前栓塞(p=0.0013)。未破裂组和破裂组供应 AVM 的动脉平均数量分别为 1.44 和 1.41(p=0.75)。未破裂组和破裂组平均栓塞的动脉数量分别为 2.51 和 1.82(p=0.003)。n-丁基氰丙烯酸酯和 Onyx 是两种最常用的栓塞剂。在 4 名患者(164 名栓塞患者中的 4 名)中出现了 4 例并发症:2 例围手术期/术后出血,1 例夹层,1 例梗死。所有接受手术的患者术后血管造影均完全治愈。患者平均随访 55 个月。未破裂 AVM 患者中 92.5%和破裂 AVM 患者中 88.0%的患者获得了良好的长期结果(mRS 评分≤2)。永久性神经功能障碍发生率为 1.2%。 结论:在某些情况下,SM I-II AVM 可采用血管内栓塞联合显微切除术或放射外科手术进行根治性治疗,其发病率非常低,治愈率高。与其他已发表的系列研究相比,这些结果表明术前栓塞是一种安全有效的辅助治疗方法。长期随访显示,接受手术切除或放射外科治疗的低级别 AVM 患者具有良好的功能结果。

相似文献

[1]
Curative treatment for low-grade arteriovenous malformations.

J Neurointerv Surg. 2019-7-12

[2]
Safety and outcome of combined endovascular and surgical management of low grade cerebral arteriovenous malformations in children compared to surgery alone.

Eur J Radiol. 2019-2-18

[3]
Neurological morbidity and mortality associated with the endovascular treatment of cerebral arteriovenous malformations before and during the Onyx era.

J Neurosurg. 2015-6

[4]
Microsurgery for cerebral arteriovenous malformations: subgroup outcomes in a consecutive series of 288 cases.

J Neurosurg. 2016-6-10

[5]
Current surgical results with low-grade brain arteriovenous malformations.

J Neurosurg. 2015-4

[6]
Radiosurgery as a microsurgical adjunct: outcomes after microsurgical resection of intracranial arteriovenous malformations previously treated with stereotactic radiosurgery.

J Neurosurg. 2022-1-1

[7]
Microsurgical treatment of arteriovenous malformations in pediatric patients: the Boston Children's Hospital experience.

J Neurosurg Pediatr. 2015-1

[8]
A Retrospective Cohort Analysis of Hemorrhagic Arteriovenous Malformations Treated with Combined Endovascular Embolization and Gamma Knife Stereotactic Radiosurgery.

World Neurosurg. 2019-2

[9]
A treatment paradigm for high-grade brain arteriovenous malformations: volume-staged radiosurgical downgrading followed by microsurgical resection.

J Neurosurg. 2015-2

[10]
Microsurgery for intracranial arteriovenous malformation: Long-term outcomes in 445 patients.

PLoS One. 2017-3-21

引用本文的文献

[1]
From rupture to recovery: A case report on a multidisciplinary approach to arteriovenous malformation (AVM)-associated intracerebral hemorrhage.

Radiol Case Rep. 2025-5-15

[2]
Predicting intraoperative major blood loss in microsurgery for brain arteriovenous malformations.

Front Med (Lausanne). 2024-8-7

[3]
Enhancing the quality of evidence, comparability, and reproducibility in brain arteriovenous malformations treated with open surgery research: a systematic review and proposal of a reporting guideline for surgical and clinical outcomes.

Neurosurg Rev. 2024-4-21

[4]
Impact of tailored multimodal treatment for unruptured brain arteriovenous malformation: comparison with a randomized trial of unruptured brain arteriovenous malformations.

Acta Neurochir (Wien). 2023-12

[5]
Multimodal treatments of brain arteriovenous malformations: a comparison of microsurgical timings after endovascular embolization.

Ann Transl Med. 2022-7

[6]
Intraoperative Monitoring Cerebral Blood Flow During the Treatment of Brain Arteriovenous Malformations in Hybrid Operating Room by Laser Speckle Contrast Imaging.

Front Surg. 2022-5-6

[7]
Efficacy and safety of embolization for arteriovenous malformations of the basal ganglia and thalamus via the transarterial approach.

Ann Transl Med. 2022-3

[8]
Multimodality Treatment of Brain Arteriovenous Malformations with One-Staged Hybrid Operation: Clinical Characteristics and Long-Term Prognosis.

Dis Markers. 2022

[9]
Chinese Cerebrovascular Neurosurgery Society and Chinese Interventional & Hybrid Operation Society, of Chinese Stroke Association Clinical Practice Guidelines for Management of Brain Arteriovenous Malformations in Eloquent Areas.

Front Neurol. 2021-6-9

[10]
Comparing health-related quality of life in modified Rankin Scale grades: 15D results from 323 patients with brain arteriovenous malformation and population controls.

Acta Neurochir (Wien). 2021-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索